Legacy Wealth Asset Management LLC Has $1.54 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Legacy Wealth Asset Management LLC lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,753 shares of the medical research company’s stock after selling 896 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Edwards Lifesciences were worth $1,536,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JFS Wealth Advisors LLC raised its position in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. Seascape Capital Management increased its stake in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after buying an additional 174 shares during the period. Cooper Financial Group raised its position in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after acquiring an additional 175 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its stake in shares of Edwards Lifesciences by 1.2% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after acquiring an additional 184 shares during the period. Finally, Martin Capital Advisors LLP boosted its holdings in Edwards Lifesciences by 0.7% in the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after acquiring an additional 186 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 0.6 %

Edwards Lifesciences stock opened at $69.87 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $71.91 and a 200-day moving average of $71.61. The stock has a market capitalization of $41.21 billion, a PE ratio of 10.08, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business earned $0.59 EPS. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Robert W. Baird dropped their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.